Found 48 PDF associated with tag : Multiple sclerosis treatment
Abstract—Multiple sclerosis (MS) is a chronic disease affecting the central nervous system, usually leading to early disablement in young adults. At least 350,000 persons in Europe have the disease. Wide variations exist both between and within European countries in the incidence and prevalence of the disease as well as in the general standard of care for MS patients
Multiple sclerosis was thought to be an intermittent disease with inflammatory breakdown of myelin in patches in the white matter It is now evident that the disease is more continuous, with diffuse changes in the white and grey matter, breakdown of myelin, and damage to axons The McDonald criteria allow earlier confirmation of the diagnosis of multiple sclerosis and earlier decisions on therapy
Reports from four countries describing benefits from hyperbaric oxygen Therapy (HBOT) in the 1970's led to the first controlled trial conducted at New York University which was published in the New England Journal of Medicine in 1983. The outcome was very positive (p<0.0001),1 despite choosing chronic progressive or stable patients with a minimum disease duration of over 11 years. The patients were matched and randomly allocated to treatment or control groups and examinations were conducted before, during and after a course of treatment by masked observers
National Multiple Sclerosis Society recommendations are firmly rooted in the basic and clinical information available from studies to date and in their limitations. Although it is clear that cannabinoids have potential both for the management of MS symptoms such as pain and spasticity, as well as for neuroprotection, the Society cannot at this time recommend that medical marijuana be made widely available to people with MS for symptom management
The emotionalism and political maneuvering surrounding claims and counterclaims for the use of hyperbaric oxygenation therapy (HBOT) in multiple sclerosis (MS) has been nearly unique in intensity. Though widely used throughout the world, the application of HBOT in central nervous system conditions in general remains a subject of great debate, even among physicians specializing in hyperbaric medicine
Is it an autoimmune disease? • And if so what is the degree of inflammation? • Are the components of inflammation different than RRMS and if so, can we measure the components by current techniques? • Is there a greater degree of neurodegeneration and therefore novel treatments need to be developed? • Or is PPMS similar to RRMS, consisting of an inflammatory phase early in the disease with a concurrent, and later on in the course, predominant degenerative phase
Effects of a pulsed electromagnetic therapy on multiple sclerosis fatigue and quality of life: a double-blind, placebo controlled trial. Lappin MS, Lawrie FW, Richards TL, Kramer ED. Energy Medicine Developments, (North America), Inc., Burke, Va., USA. CONTEXT: There is a growing literature on the biological and clinical effects of pulsed electromagnetic fields.
This analysis was prepared for the Technology Assessment Unit (TAU) of the McGill University Health Centre (MUHC) by Chantal Bourgault PhD, Medical Scientist of the TAU. and Maurice McGregor MD, Cardiology Division, MUHC. and approved and adopted by the committee of the TAU: J. Barkun, W. Brodie, J. Brophy, J. Johnston, M. Kaplow, J. MacPhail, G. Pekeles, R. Rajan, J. Ritchie, F. Salevsky, S. Suissa, M. McGregor. With the additional members: J. Antel, D.Arnold, A.Bar-Or, J.Chambers-Evans, Y.Lapierre and A. Lynch.
The fundamentals of the Ayurvedic system are in treating the individual by taking his unique constitutional aspect and prescribing an herbal counterpart that is against the disease and that supports his constitution (system). Ayurvedic treatments for neurological diseases have proved highly successful. I am practicing Ayurveda as a third generation Vaidya (Ayurvedic Physician) from my family, the Raghavans from Kerala, India,